Skip to main content
. 2014 Jan 28;11(2):249–256. doi: 10.4314/ajtcam.v11i2.4

Table 5.

Effect of Diabegon® on kidney functions in MetS with Non-insulin dependent diabetes mellitus subjects of different age groups (N=58)

(Group) Urea (mg/dl) Uric acid (mg/dl) Creatinine (mg/dl)
Initial (a) 6 month of
therapy (b)		 12 month
of
therapy(c)		 18 month
of therapy(d)		 Initial
(a)		 6 month of
therapy (b)		 12 month
of therapy (c)		 18 month
of therapy (d)		 Initial
(a)		 6 month of
therapy (b)		 12 month
of therapy(c)		 18 month
of therapy(d)
Group I
(35–50) ,N=10 		20.4±7.4 23.1±10.1 25.6±3.3 23.9±4.5 5.65±1.7 4.9±2.7 4.8±1.1 5.1±.2 1.6±.59 1.2±.38 0.5±.13
a**b**		 0.74±.12
a**b*c*
Group II
(51–65) ,N=34 		30±5.9 17.6±2.9 a** 25.6±5.9
a*b**		 21.1±4.3
a**b**c**		 6.0±2.1 5.5±2.7 6.1±2 7.6±.66
a**b**c**		 1.0±.106 0.91±.38 0.805±.27
a**		 1±.13
c**
Group III >65,
N=14 		27.4±5.8 26.6±.2 21.9±1.5
a*b**		 21.3±10.5 7.2±.47 6.2±1.2
a*		 4.3±1.5
a**b**		 5.7±1.9
a*c*		 1.17±.86 1.1±.52 0.83±.2
b*		 0.6±.4
a*b*
CB-IV, N=43
FBS<145.9 		35.4±11.5 28±2
a**		 24.2±5.2
a**b **		 25.1±5.2 a**b** 4.9±1.1 6.9±1.7
a**		 5.5±.90
a**b**		 6.4±1.8
a**c*		 1.4±.67 1.1±.37
a*		 0.8±.29
a**b**		 0.8±.5
a**b**
CB-V, N=15
FBS>145.9 		23.3±7.3 27.6±1.2
a*		 25.4±4.6 27±16 8.8±.98 6.7±.77
a**		 5.9±.7
a**b**		 5.7±1.7
a**b*		 .96±.44 0.84±.32 0.97±.58 0.70±.26